GSK PLC

GSK PLC’s stock price has surged following significant developments, including partnerships worth up to $20.75 billion and $120 billion, increasing trading volume and investor interest.

GSK PLC reports strong quarterly earnings, with profit per share and revenue increasing significantly compared to the same period last year.

GSK PLC is set to release its quarterly earnings on July 30, 2025, with analysts expecting a decline in earnings per share despite a potential increase in revenue.

GSK has made a $12 billion bet on China’s growing influence in the pharmaceutical market, partnering with Hengrui Pharma to develop up to 12 innovative medicines.

GSK PLC’s plans for its multiple myeloma treatment Blenrep have been put on hold after the FDA delayed its decision on the drug’s approval.

GSK PLC’s stock price plummeted 5% after a US FDA advisory panel recommended against its blood cancer medication, Blenrep, due to eye safety risks.

GSK PLC is set to release its quarterly earnings on July 30, 2025, with analysts predicting a significant increase in earnings per share.

GSK has completed the acquisition of efimosfermin, a groundbreaking liver disease drug, marking a major milestone in its efforts to expand its portfolio and solidify its position in the pharmaceutical sector.

GSK’s stock price has been fluctuating due to a recent study and share buyback program, raising questions about the company’s priorities and long-term sustainability.

GSK PLC’s stock price has fluctuated over the past few years, but recent developments, including FDA approval for a new lupus treatment, have sparked mixed analyst recommendations and a positive start to the week for the FTSE 100 index.